Department of Rheumatology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Republic of Korea.
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea.
Clin Exp Med. 2021 Aug;21(3):399-406. doi: 10.1007/s10238-021-00691-2. Epub 2021 Feb 20.
We previously reported that fibrosis-4 (FIB-4) was associated with poor outcomes of microscopic polyangiitis (MPA) and granuloma with polyangiitis (GPA). We also investigated the potential of FIB-5, a novel index, in predicting all-cause mortality and end-stage renal disease (ESRD) during follow-up in patients with MPA and GPA without substantial liver diseases. Clinical and laboratory data at diagnosis were collected by reviewing the medical records of 180 patients with MPA and GPA. FIB-5 was obtained by a following equation: FIB-5 = (serum albumin (g/L) × 0.3 + platelet count (10/L) × 0.05) - (alkaline phosphatase (IU/L) × 0.014 + aspartate aminotransferase/alanine aminotransferase ratio × 6 + 14). The median age of the patients at diagnosis was 61.0 years. FIB-5 at diagnosis could not reflect the cross-sectional vasculitis activity. The cutoffs of FIB-5 for poor outcomes was set as 0.82 (the lowest tertile) and -0.42 (the lowest quartile) at diagnosis. In Kaplan-Meier survival analysis, patients with FIB-5 < 0.82 and those with FIB-5 < -0.42 exhibited lower ESRD-free survival rates than those without. However, it could not predict all-cause mortality. In multivariable Cox hazards analysis, both FFS (Hazard ratio (HR) 1.554) and FIB-5 < 0.82 (HR 2.096) as well as both FFS (HR 1.534) and FIB-5 < -0.42 (HR 2.073) at diagnosis independently predicted ESRD during follow-up. In conclusion, FIB-5 < 0.82 and FIB-5 < -0.42 at diagnosis could predict the occurrence of ESRD, but not all-cause mortality, during follow-up in patients with MPA and GPA without substantial liver diseases.
我们之前报道过纤维化-4(FIB-4)与显微镜下多血管炎(MPA)和肉芽肿性多血管炎(GPA)的不良预后相关。我们还研究了 FIB-5(一种新的指数)在预测无明显肝脏疾病的 MPA 和 GPA 患者随访期间全因死亡率和终末期肾病(ESRD)的潜力。通过回顾 180 例 MPA 和 GPA 患者的病历收集了诊断时的临床和实验室数据。FIB-5 通过以下公式获得:FIB-5=(血清白蛋白(g/L)×0.3+血小板计数(10/L)×0.05)-(碱性磷酸酶(IU/L)×0.014+天冬氨酸转氨酶/丙氨酸转氨酶比值×6+14)。患者诊断时的中位年龄为 61.0 岁。诊断时的 FIB-5 不能反映横断面血管炎活动。将 FIB-5 的截断值设定为 0.82(最低三分位)和-0.42(最低四分位)以预测不良结局。在 Kaplan-Meier 生存分析中,FIB-5<0.82 和 FIB-5<-0.42 的患者的 ESRD 无生存率低于无上述情况的患者。然而,它不能预测全因死亡率。在多变量 Cox 风险分析中,FFS(危险比(HR)1.554)和 FIB-5<0.82(HR 2.096)以及 FFS(HR 1.534)和 FIB-5<-0.42(HR 2.073)均在诊断时独立预测随访期间的 ESRD。总之,诊断时的 FIB-5<0.82 和 FIB-5<-0.42 可预测无明显肝脏疾病的 MPA 和 GPA 患者随访期间 ESRD 的发生,但不能预测全因死亡率。